Mylan's Growth Strategy: The EpiPen Revolution

In 2007, pharmaceutical company Mylan acquired Merck and their multibillion dollar generics business under CEO Robert Coury. Coury immediately appointed one of his top executives, Heather Bresch, to integrate the new products into the company’s pipeline. Bresch became Mylan’s COO later that year and decided to focus primarily on the Epipen, a spring-loaded syringe device created to deliver an exact dose of epinephrine, a severe allergy life-saving drug which immediately reverses life-threatening reactions to bee stings, peanuts, and other allergens.
Ms. Bresch is considered to be an insider in the pharmaceutical industry. Her father is a United States senator and she runs of the biggest generic drug companies in the world. She also oversees the Generic Pharmaceutical Association, an industry’s lobbying group. Running public awareness campaigns and releasing several press releases on the dangers of anaphylactic shock in children; the company’s lobbyists pressed for legislation to make available Epipen devices mandatory at schools. At the same time, significantly due to Bresch’s

Particularly in the pharmaceutical industry in which companies are given patents for products and have to profit as much as possible before the end of such. This fact, under Nozick’s views, is considered ethical even if companies are sharply increasing prices from one day to another for a life-saving drug. Ms. Bresch is not hiding the fact that her company is a for-profit and that it has to create revenue. In a CNBC interview on August 25, 2016, the interviewer asked her that “given the firestorm that surround us (in the media), are the price hikes for Mylan done?”. Ms. Bresch did not hesitate and calmly responded, “we’ll continue to run a business, and we are going to continue to meet the supply and demand of what’s out